在ApoE-/-小鼠模型中,3-基酸体内给药对心脏代谢疾病的影响
Viviana Casagrande1, Luca Panarello1, Alessio Lepri1
1Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy.
Pharmacological research
|September 10, 2025
概括
通过改善脂肪酸氧化和肝功能,3-基酸盐 (3-HIB) 治疗减少了小鼠的动脉样硬化. 这种氨酸催化剂显示出对心血管疾病治疗的潜力.
科学领域:
- 生物化学 生物化学
- 代谢研究研究 代谢研究
- 心血管科学 心血管科学
背景情况:
- 3-基酸 (3-HIB) 是一种氨酸催化剂,与脂肪酸吸收和脂质代谢有关.
- 3-HIB影响这些过程的确切机制,特别是在动脉样硬化的情况下,仍然不清楚.
研究的目的:
- 研究3-HIB治疗对动脉样硬化,脂质代谢和肝损伤的长期影响.
- 在ApoE-/-小鼠模型中阐明3-HIB作用背后的分子机制.
主要方法:
- 向食西方饮食的ApoE-/-小鼠进行了长期的3-HIB治疗.
- 分析了动脉样硬化病变的发展,血清脂质概况,肝功能标志物和基因表达.
- 在HepG2细胞中进行实验,以确认细胞机制.
主要成果:
- 3-HIB治疗显著降低了体重,血清脂质和大动脉斑块面积.
- 改善肝功能和调节参与昼夜节律和脂肪酸氧化中的基因.
- 证实了3-HIB与昼夜基因的联系,并在肝细胞中增加细胞内乙-CoA,增强脂肪酸氧化和ATP生成.
结论:
- 3-HIB治疗在ApoE-/-小鼠中显示出对动脉样硬化的保护作用.
- 该机制涉及增强的脂肪酸氧化,部分由昼夜基因调制介导.
- 3-HIB为心血管疾病提供了潜在的治疗策略.
相关概念视频
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:26Atherosclerosis III: Management
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...